KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Working Capital Changes (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Other Working Capital Changes for 6 consecutive years, with -$3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 37.93% year-over-year to -$3.1 million, compared with a TTM value of -$17.1 million through Dec 2025, down 188.01%, and an annual FY2025 reading of -$17.1 million, down 188.01% over the prior year.
  • Other Working Capital Changes was -$3.1 million for Q4 2025 at AbCellera Biologics, up from -$23.4 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $13.3 million in Q1 2025 and bottomed at -$23.4 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is -$1.3 million, with a median of $503500.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes tumbled 959.65% in 2022, then surged 2036.84% in 2024.
  • Year by year, Other Working Capital Changes stood at $4.8 million in 2021, then rose by 2.44% to $5.0 million in 2022, then tumbled by 381.1% to -$13.9 million in 2023, then soared by 64.5% to -$4.9 million in 2024, then soared by 37.93% to -$3.1 million in 2025.
  • Business Quant data shows Other Working Capital Changes for ABCL at -$3.1 million in Q4 2025, -$23.4 million in Q3 2025, and -$4.0 million in Q2 2025.